1. Home
  2. CAPR vs HMN Comparison

CAPR vs HMN Comparison

Compare CAPR & HMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$19.50

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Horace Mann Educators Corporation

HMN

Horace Mann Educators Corporation

HOLD

Current Price

$51.58

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAPR
HMN
Founded
2005
1945
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
CAPR
HMN
Price
$19.50
$51.58
Analyst Decision
Strong Buy
Buy
Analyst Count
8
3
Target Price
$44.63
$47.33
AVG Volume (30 Days)
1.7M
282.4K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
3.05%
EPS Growth
N/A
57.26
EPS
N/A
1.00
Revenue
N/A
$1,701,400,000.00
Revenue This Year
N/A
$6.91
Revenue Next Year
$3.31
$3.41
P/E Ratio
N/A
$52.38
Revenue Growth
N/A
6.66
52 Week Low
$4.30
$40.54
52 Week High
$40.37
$55.56

Technical Indicators

Market Signals
Indicator
CAPR
HMN
Relative Strength Index (RSI) 28.96 56.01
Support Level $5.25 $41.72
Resistance Level $30.39 $55.56
Average True Range (ATR) 1.33 1.24
MACD -0.26 -0.30
Stochastic Oscillator 16.93 24.87

Price Performance

Historical Comparison
CAPR
HMN

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About HMN Horace Mann Educators Corporation

Horace Mann Educators Corp is a diversified insurance holding company that markets and underwrites personal lines of property and casualty insurance, retirement annuities, and life insurance. The company's property and casualty operations focus on automobile and homeowner insurance, while the retirement annuities are tax-qualified products. Horace Mann Educators markets its products to kindergarten through 12th-grade teachers, administrators, and other employees of public schools and their families. The Company conducts and manages its business in four reporting segments: (1) Property & Casualty, (2) Life & Retirement, (3) Supplemental & Group Benefits and (4) Corporate & Other.

Share on Social Networks: